Clinical trial
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
NCT00455975 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00455975 |
|---|---|
| Title | High-dose Bevacizumab in Advanced Renal Carcinoma Patients |
| Official title | Phase II Trial of High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cancer, Kidney Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab |
| Enrollment | 119 |
| Start date | Feb 1, 2007 |
| Primary completion | Jul 1, 2013 |
| Completion | Sep 1, 2013 |
| First posted | Apr 4, 2007 |
| Last update posted | Dec 22, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: